­
­
­
­

Inventi Impact - Pharm Biotech & Microbio

Patent Watch

  • Glycopegylated granulocyte colony stimulating factor

    The present invention provides conjugates between Granulocyte Colony Stimulating Factor and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention.

  • Attenuated gram negative bacteria

    Disclosed and claimed are a mutant of a gram negative bacterium, wherein said bacterium has at least one mutation in a nucleotide sequence which codes for a polypeptide having an identity which is equal or more than 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% with an amino acid sequence coded by a nucleotide sequence selected from the group consisting of nucleotide sequences identified SEQ ID NO: 2, 6, 9, 12, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 75, 78, 81, 84, 87, 90, 93; said mutation resulting in attenuated virulence of the bacterium. Immunogenic compositions and vaccines containing such a mutant are also disclosed and claimed.

  • STAT3 phosphorylation inhibitor and notch1 expression inhibitor

    The present invention relates to an agent for suppressing STAT3 phosphorylation and for suppressing Notch1 expression comprising as an active ingredient a compound represented by the following formula (1): ##STR00001## wherein R.sup.1, R.sup.2 and R.sup.3 each independently represents a hydrogen atom or a methyl group; and X represents a linear or branched alkyl, alkylene or alkenylene group having 10 to 28 carbon atoms.

  • Human antibody molecules for IL-13

    Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.

  • Direct antimicrobial susceptibility assay

    An antimicrobial susceptibility assay, including the steps of: providing an assay dish; providing a growth medium in said dish; providing an antimicrobial agent sample; providing an interpretive indication located a predetermined distance from a sample location adjacent the growth medium in the assay dish; providing an interfitting element which interfits with said dish, said interfitting element configured to enable at least one the steps of: a) more accurately positioning the antimicrobial sample at the sample location in contact with the growth medium; b) providing the interpretive indication at a predetermined distance from said sample position to enable said interpretative indication to be compared with a margin of a zone of inhibition of a colony grown on said medium to determine an assay result, wherein said result can include determination of at least one of: a) "susceptible;" "intermediate;" and, "resistant;" placing a microorganism on the growth medium; placing the antimicrobial agent sample at said sample location with accuracy using said interfitting element; incubating said microorganism for a period sufficient to allow a margin of a zone of inhibition to be discernable; and, comparing the location of the margin of the zone of inhibition to the interpretive indication, to obtain a result including a determination of at least one of a) "susceptible;" b) "intermediate;" and, c) "resistant" for said microorganism with respect to the antimicrobial agent.

  • Perhydrolase providing improved peracid stability

    An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a Thermotoga maritima acetyl xylan esterase gene was modified using error-prone PCR and site-directed mutagenesis to create an enzyme catalyst characterized by an increase in the ratio of peracetic acid formation to peracetic acid hydrolysis specific activities (PAAF/PAAH ratio). The variant acetyl xylan esterase may be used to produce peroxycarboxylic acids suitable for use in a variety of applications such as cleaning, disinfecting, sanitizing, bleaching, wood pulp processing, and paper pulp processing applications.

  • Probiotic bifidobacterial species

    A probiotic composition comprising a Bifidobacterium strain which has DNA sequence homology of greater than 40% to Bifidobacterium GC56, wherein Bifidobacterium GC56 was deposited at the Collection Nationale de Cultures de Micro-organismes (CNCM, Institut Pasteur) on 9 Dec. 2004 with accession number CNCM 1-3342.

  • Modified antigen-presenting cells

    The invention relates to antigen-presenting cells having specificity against a selected antigen and methods for making the cells. The invention also relates to a method of selecting efficient antigen-presenting cells using reporter fusion constructs. The highly efficient antigen-presenting cells of the invention will provide a therapeutic strategy of modulating immune responses for a variety of diseases.

  • Laccase enzyme and use thereof

    The present invention relates to a novel laccase enzyme obtainable from the strains of genus Thielavia. The invention relates also to the nucleic acid sequence encoding the enzyme, a recombinant host into which the nucleic acid sequence has been introduced and a method for the production of the enzyme in a recombinant host. The enzyme of the invention is suitable for several applications, in particular for increasing the lightness of denim.

  • VACCINES

    The invention relates to use of an antigen derived from the circumsporozoite protein (CS) protein of Plasmodium falciparum which is expressed at the pre-erythrocytic stage of malarial infection in combination with a pharmaceutically acceptable adjuvant, in the manufacture of a medicament for vaccinating infants against malaria.

  • METHODS FOR INCREASING PRODUCT YIELDS

    A non-naturally occurring microbial organism includes a microbial organism having a reductive TCA or Wood-Ljungdahl pathway in which at least one exogenous nucleic acid encoding these pathway enzymes is expressed in a sufficient amount to enhance carbon flux through acetyl-CoA. A method for enhancing carbon flux through acetyl-CoA includes culturing theses non-naturally occurring microbial organisms under conditions and for a sufficient period of time to produce a product having acetyl-CoA as a building block. Another non-naturally occurring microbial organism includes at least one exogenous nucleic acid encoding an enzyme expressed in a sufficient amount to enhance the availability of reducing equivalents in the presence of carbon monoxide or hydrogen, thereby increasing the yield of redox-limited products via carbohydrate-based carbon feedstock. A method for enhancing the availability of reducing equivalents in the presence of carbon monoxide or hydrogen includes culturing this organism for a sufficient period of time to produce a product.

  • MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF P-TOLUATE AND TEREPHTHALATE

    The invention provides non-naturally occurring microbial organisms having a (2-hydroxy-3-methyl-4-oxobutoxy)phosphonate pathway, p-toluate pathway, and/or terephthalate pathway. The invention additionally provides methods of using such organisms to produce (2-hydroxy-3-methyl-4-oxobutoxy)phosphonate pathway, p-toluate pathway or terephthalate pathway.

  • MICROORGANISM PRODUCING L-METHIONINE PRECURSOR AND THE METHOD OF PRODUCING L-METHIONINE PRECURSOR USING THE MICROORGANISM

    The present invention relates to a microorganism producing L-methionine precursor, O-acetylhomoserine, and a method of producing L-methionine precursor using the microorganism.

  • Production Process for Fine Chemicals Using Microorganisms with Reduced Isocitrate Dehydrogenase Activity

    The present invention is directed to a method utilizing a microorganism with reduced isocitrate dehydrogenase activity for the production of fine chemicals. Said fine chemicals may be amino acids, monomers for polymer synthesis, sugars, lipids, oils, fatty acids or vitamins and are preferably amino acids of the aspartate family, especially methionine or lysine, or derivatives of said amino acids, especially cadaverine. Furthermore, the present invention relates to a recombinant microorganism having a reduced isocitrate dehydrogenase activity in comparison to the initial microorganism and the use of such microorganisms in producing fine chemicals such as aspartate family amino acids and their derivatives.

  • ENHANCED ANTISENSE OLIGONUCLEOTIDES

    Described herein are gap-widened antisense oligonucleotides having improved therapeutic index as compared to 5-10-5 MOE gapmer antisense oligonucleotides of the same sequence. Also described are methods of reducing a target RNA in an animal using the gap-widened antisense oligonucleotides of the present invention. Further, are methods for selecting a gap-widened antisense oligonucleotides.

  • ISOLATED BACTERIAL STRAIN OF THE GENUS BURKHOLDERIA AND PESTICIDAL METABOLITES THEREFROM

    A species of Burkholderia sp with no known pathogenicity to vertebrates but with pesticidal activity (e.g., plants, insects, fungi, weeds and nematodes) is provided. Also provided are natural products derived from a culture of said species and methods of controlling pests using said natural products.

  • NON-INTEGRATING LENTI/ADENO-ASSOCIATED VIRUS HYBRID VECTOR SYSTEM

    The present invention provides for a hybrid vector system for the purpose of therapeutic gene delivery where the system is used for a targeted integration of a therapeutic gene into a genome. The hybrid vector system comprises a hybrid vector made up of a non-integrating lentiviral vector and an adeno-associated vector, and a therapeutic gene.

  • Targeted genomic modification with partially single-stranded donor molecules

    Disclosed herein are donor molecules comprising single-stranded complementary regions flanking one or more sequences of interest. The donor molecules and/or compositions comprising these molecules can be used in methods for targeted integration of an exogenous sequence into a specified region of interest in the genome of a cell.

  • Prevention and treatment of gram negative, flagellated bacterial infections

    The present invention describes a novel mechanism of adhesion by flagellated Gram-negative bacteria such as enterotoxigenic Escherichia coli (ETEC), where the bacteria secretes a protein, EtpA which binds to the conserved region of the flagellin protein located at the tip of the flagella. The present invention also discloses that EtpA-mediated interaction and intestinal colonization require interaction with flagellin. Also disclosed herein is a vaccine composition that can be used for either active or passive immunization of mammals for the prevention or treatment of infections caused by flagellated Gram-negative bacteria.

  • SCREENING ASSAYS FOR INHIBITORS OF A STAPHYLOCOCCUS AUREUS SIDEROPHORE

    Isolation of an iron regulated, nme-gene operon (designated sbn) from Staphylococcus aureus (RN6390), responsible for the biosynthesis of staphylobactm, a novel S. aureus siderophore Methods for treating or preventing a disease or condition caused by S. aureus infection, as well as methods for identifying agents that inhibit the biosynthesis of staphylobactm or inhibit the expression of genes in said sbn operon are further disclosed.

  • Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement

    Recombinant polynucleotides and recombinant polypeptides useful for improvement of plants are provided. The disclosed recombinant polynucleotides and recombinant polypeptides find use in production of transgenic plants to produce plants having improved properties.

  • Human Monoclonal Antibodies To Programmed Death Ligand 1 (PD-L1)

    The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.

  • Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses

    Modified human plasma polypeptides or Fc and uses thereof are provided.

  • METHOD FOR TREATING BREAST CANCER USING ADENINE NUCLEOTIDE TRANSLOCATOR 2 (ANT2) SIRNA OR ANT2 SHRNA

    The present invention relates to adenine nucleotide translocator 2 (ANT2) siRNA (small interfering RNA) or ANT2 shRNA (short hairpin RNA) suppressing the expression of ANT2 gene expression and anticancer agent containing the same. Furthermore, the present invention relates to methods for treating breast cancers or stem cells of a breast cancer by treating the same with ANT2 siRNA or ANT2 shRNA. In addition, the invention provides a method for inhibiting metastasis of breast cancer cells with ANT2 siRNA or ANT2 shRNA.

  • Materials and Methods Involving Hybrid Vascular Endothelial Growth Factor DNAs and Proteins

    The present invention provides polypeptides that bind cellular receptors for vascular endothelial growth factor polypeptides; polynucleotides encoding such polypeptides; compositions comprising the polypeptides and polynucleotides; and methods and uses involving the foregoing. Some polypeptides of the invention exhibit unique receptor binding profiles compared to known, naturally occurring vascular endothelial growth factors.

  • Novel Genes, Compositions, and Methods for Modulating the Unfolded Protein Response

    The present invention relates to methods and compositions for modulating the unfolded protein response. The method further relates to methods and compositions for the treatment and diagnosis of protein conformational diseases or disorders, including, but not limited to, .alpha.1-antitrypsin deficiency, cystic fibrosis, and autoimmune diseases and disorders. The invention further provides methods for modulating the unfolded protein response by modulating XBP1 mRNA splicing.

  • MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF PROPYLENE

    The invention provides non-naturally occurring microbial organisms having a propylene pathway. The invention additionally provides methods of using such organisms to produce propylene.

  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD274/PD-L1 GENE

    The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CD274/PD-L1 gene, and methods of using such dsRNA compositions to inhibit expression of CD274/PD-L1.

  • COMPOUND, MEDICAMENT, VACCINE COMPOSITION AND NANOCAPSULES

    The present invention relates to a compound comprising a polyelectrolyte and, covalently linked thereto, an immunological adjuvant and/or cell targeting ligand, wherein the covalently linked entity can have both adjuvant and cell targeting characteristics. The compound is used in the preparation of hydrophilic vaccine nanoparticles, which preferably have an antigenic compound or therapeutic agent, or genetic information encoding such compounds or agents entrapped in their matrix, or covalently linked to their surfaces. Vaccine compositions comprising the particles of the invention are advantageous, because a strong and long-lasting immune response is obtained following administration of a single dose. In a preferred embodiment, the polyelectrolyte of the compound is an anionic polymer, and the particle comprises a matrix comprising chitosan.

  • Horizontal Plate Microbial Support Media

    A horizontal plate microbial support media. The horizontal plate microbial support media having a plurality of frustum shaped protuberances extending there-from, the frustum shapes having a hole in their upper base for allowing fluid to flow there-through. These media plates able to be stacked for use in a bioreactor.

  • EVALUATING GENETIC DISORDERS

    The present invention relates to genetic analysis and evaluation utilizing copy-number variants or polymorphisms. The methods utilize array comparative genomic hybridization and PCR assays to identify the significance of copy number variations in a subject or subject group.

  • INSECTICIDAL PROTEINS FROM BACILLUS THURINGIENSIS

    The invention pertains to novel insecticidal compounds derived from Bacillus thuringiensis strains. New proteins designated Cry1Jd, Cry9Fa, and Cry1Bf, and insecticidal fragments thereof are provided, as well as DNA sequences encoding these proteins or their insecticidal fragments. Further provided are recombinant hosts expressing such proteins, particularly plant cells and plants.

  • Method and Apparatus for Rapid Nucleic Acid Sequencing

    Methods and apparatus relating to FET arrays including large FET arrays for monitoring chemical and/or biological reactions such as nucleic acid sequencing-by-synthesis reactions. Some methods provided herein relate to improving signal (and also signal to noise ratio) from released hydrogen ions during nucleic acid sequencing reactions.

  • MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Ovarian Cancer Using a Real-Time PCR Platform

    Methods and compositions for the diagnosis, prognosis and/or treatment of ovarian cancer are disclosed.

  • RECOMBINANT VACCINIA VIRUS HAVING HEPATITIS C VIRUS GENE

    Provided is a recombinant virus which is efficacious in preventing the onset of hepatitis C infection and has a high safety. Also provided is a vaccine for hepatitis C virus which contains the recombinant virus. A recombinant vaccinia virus which can express hepatitis C virus gene. The hepatitis C virus vaccine as described above contains the recombinant virus as described above.

  • HIV VACCINES BASED ON ENV OF MULTIPLE CLADES OF HIV

    In one embodiment, the invention provides a multiclade HIV plasmid DNA or viral vector vaccine including components from different clades of Env (optionally Env chimeras) and Gag-Pol-(optionally)Nef from a singlr clade. The vaccine of the invention may further include V1, V2, V3, or V4 deletions or combinations thereof. In another embodiment, the invention provides multiclade HIV envelope immunogens.

  • CAPSULAR GRAM-POSITIVE BACTERIA BIOCONJUGATE VACCINES

    The present invention encompasses a novel S. aureus bioconjugate vaccine. More generally, the invention is directed to Gram-positive and other bioconjugate vaccines containing a protein carrier, at least one polysaccharide such as a capsular Gram-positive polysaccharide, and, optionally, an adjuvant or pharmaceutically acceptable carrier. The instant invention also includes methods of producing Gram-positive and other bioconjugate vaccines. An N-glycosylated protein is also provided that contains one or more polysaccharides such as Gram-positive polysaccharides. The invention is additionally directed to engineered prokaryotic organisms comprising nucleotide sequences encoding a glycosyltransferase of a first prokaryotic organism and a glycosyltransferase of a second prokaryotic organism. The invention further includes plasmids and prokaryotic cells transformed with plasmids encoding polysaccharides and enzymes which produce an N-glycosylated protein and/or bioconjugate vaccine. Further, the invention is directed to methods of inducing an immune response in a mammal comprising administering said bioconjugate vaccines.

  • Broad Spectrum Vaccine Against Non-Typhoidal Salmonella

    The present invention is drawn to attenuated Salmonella serovar strains S. Typhimurium and S. Enteritidis, conjugate vaccines derived from these attenuated strains of S. Typhimurium and S. Enteritidis, comprising an O polysaccharide covalently linked to a flagellin protein, and methods for inducing an immune response in a subject comprising administering the attenuated strains and/or the conjugate vaccines of the invention.

  • LONG LASTING DRUG FORMULATIONS

    The present invention is directed to long-lasting erythropoietin therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes erythropoietin.

  • Single Use Bead Mill

    The present invention relates to a device that incorporates a single use bead mill that is at least partially sterilized prior to use in the pharmaceutical, biopharmaceutical, biotechnology or related industries and is used for the disruption of cells or for homogenization within one or more fluid streams and is connected to a bioreactor, fermentor, container or process by way of single use tubing, connectors and/or various fluid flow components.

  • ANTIBIOTIC PEPTIDES

    The invention relates to a peptide or peptide derivative having the general formula: Sub.sub.1-X.sub.1-D.sub.2K.sub.3-P.sub.4-P.sub.5-Y.sub.6-L.sub.7-P.sub.8-- R.sub.9-P.sub.10-X.sub.2-P.sub.12-P.sub.13-R.sub.14-X.sub.3-I.sub.16-P.sub- .17/Y.sub.17-N.sub.18-N.sub.19-X.sub.4-Sub.sub.2, wherein X.sub.1 is a non-polar, hydrophobic group or a positively charged group, D.sub.2 is asparagine or glutamine, K.sub.3, X.sub.2, and X.sub.4 are positively charged groups, X.sub.3 is a positively charged group, proline, or a proline derivative; L.sub.7 and I.sub.16 are non-polar, hydrophobic groups, Y.sub.6 and Y.sub.17 are tyrosine, R.sub.9 and R.sub.14 are arginine, N.sub.18 and N.sub.19 are asparagine or glutamine, P.sub.4, P.sub.5, P.sub.8, P.sub.10, P.sub.12, P.sub.13, and P.sub.17 are proline, hydroxyproline, or derivatives thereof, wherein possibly one or two of the groups selected from D.sub.2, P.sub.4, P.sub.5, P.sub.8, P.sub.10, P.sub.12, P.sub.13, P.sub.17, and Y.sub.17 are replaced by an arbitrary group and/or P.sub.13 and R.sub.14 are exchanged, Sub.sub.1 is the free or modified N-terminus, and Sub.sub.2 is the free or modified C-terminus. The invention further relates to the use of the peptides and peptide derivatives in medicine, as an antibiotic, in a disinfectant or cleaning agent, as a preservative or in a packaging material, in pharmaceutical research, or in a screening method.

  • MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF AROMATICS, 2,4-PENTADIENOATE AND 1,3-BUTADIENE

    The invention provides non-naturally occurring microbial organisms having a toluene, benzene, p-toluate, terephthalate, (2-hydroxy-3-methyl-4-oxobutoxy)phosphonate, (2-hydroxy-4-oxobutoxy)phosphonate, benzoate, styrene, 2,4-pentadienoate, 3-butene-1ol or 1,3-butadiene pathway. The invention additionally provides methods of using such organisms to produce toluene, benzene, p-toluate, terephthalate, (2-hydroxy-3-methyl-4-oxobutoxy)phosphonate, (2-hydroxy-4-oxobutoxy)phosphonate, benzoate, styrene, 2,4-pentadienoate, 3-butene-1ol or 1,3-butadiene.

  • METHODS FOR DETECTING A MYCOBACTERIUM TUBERCULOSIS INFECTION

    Methods for detecting an infection with Mycobacterium tuberculosis (Mtb) in a subject are disclosed. The methods include detecting the presence of CD8+ T cells that specifically recognize an Mtb polypeptide. The methods include in vitro assays for detecting the presence of CD8+ T cells in a biological sample, and in vivo assays that detect a delayed type hypersensitivity reaction. The methods can also include detecting Mtb polypeptides and polynucleotides. Reagents for the detection of an Mtb infection are also disclosed.

  • Attenuated Gram Negative Bacteria

    Disclosed and claimed are a mutant of a gram negative bacterium, wherein said bacterium has at least one mutation in a nucleotide sequence which codes for a polypeptide having an identity which is equal or more than 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% with an amino acid sequence coded by a nucleotide sequence selected from the group consisting of nucleotide sequences identified SEQ ID NO: 2, 6, 9, 12, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 75, 78, 81, 84, 87, 90, 93; said mutation resulting in attenuated virulence of the bacterium. Immunogenic compositions and vaccines containing such a mutant are also disclosed and claimed.

  • Vaccines Based on Targeting Antigen to DCIR Expressed on Antigen-Presenting Cells

    The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.

  • ANTI-LYMPHOTOXIN ANTIBODIES

    The instant invention is based, at least in part on the identification of a new class of antibodies that result, e.g., in improved LT blocking capabilities. Methods of making the subject binding molecules and methods of using the binding molecules of the invention to antagonize LT.beta.R signaling are also provided.

  • POLYESTERS WITH GRAFTED ZWITTERIONS

    The invention relates to polymers, such as aliphatic polyesters, with grafted zwitterions. More particularly, the invention relates to polyester-graft-phosphorylcholine polymers prepared by ring-opening polymerization and click chemistry, compositions and products comprising same, and related methods and uses, for example, in drug delivery.

  • SPANX-B POLYPEPTIDES AND THEIR USE

    It is disclosed herein that SPANX-B is uniquely expressed in a number of human tumors and that SPANX-B is an immunogenic antigen that is recognized by human T cells inducing helper CD4.sup.+ and cytolytic CD8.sup.+ T cell responses. Specific SPANX-B polypeptides and polynucleotides are disclosed that can be used to generate an immune response. In several embodiments, these polypeptides can be used for the treatment of a variety of cancers, including melanoma, colon carcinoma, ovarian cancer, breast cancer, myeloma, lung carcinoma and renal cancer.

  • Albumin variants and conjugates

    Based on the three-dimensional structure of albumin, the inventors have designed variant polypeptides (muteins) which have one or more cysteine residues with a free thiol group (hereinafter referred to as "thio-albumin"). The variant polypeptide may be conjugated through the sulphur atom of the cysteine residue to a conjugation partner such as a bioactive compound.

  • MICROORGANISMS AND METHODS FOR THE PRODUCTION OF ETHYLENE GLYCOL

    The invention provides non-naturally occurring microbial organisms having an ethylene glycol pathway. The invention additionally provides methods of using such organisms to produce ethylene glycol.

  • Predicting Human Developmental Toxicity of Pharmaceuticals Using Human Stem-Like Cells and Metabolomics

    The invention provides biomarker profiles of metabolites and methods for screening chemical compounds including pharmaceutical agents, lead and candidate drug compounds and other chemicals using human stem-like cells (hSLCs) or lineage-specific cells produced therefrom. The inventive methods are useful for testing toxicity, particularly developmental toxicity and detecting teratogenic effects of such chemical compounds. Specifically, a more predictive developmental toxicity model, based on an in vitro method that utilizes both hSLCs and metabolomics to discover biomarkers of developmental toxicity is disclosed.

  • Predicting Human Developmental Toxicity of Pharmaceuticals Using Human Stem-Like Cells and Metabolomics

    The invention provides biomarker profiles of metabolites and methods for screening chemical compounds including pharmaceutical agents, lead and candidate drug compounds and other chemicals using human stem-like cells (hSLCs) or lineage-specific cells produced therefrom. The inventive methods are useful for testing toxicity, particularly developmental toxicity and detecting teratogenic effects of such chemical compounds. Specifically, a more predictive developmental toxicity model, based on an in vitro method that utilizes both hSLCs and metabolomics to discover biomarkers of developmental toxicity is disclosed.

  • Interferon Alpha Antibodies And Their Uses

    The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.

  • Purification Process

    A process for purifying a transferrin solution and the product of the purification process. A process for producing transferrin and the product of the production process. Use of the transferrin in cell culture, as a pharmaceutical ingredient, as a pharmaceutical product and in a cell culture medium.

  • METHODS AND SYSTEMS FOR SIMULTANEOUS REAL-TIME MONITORING OF OPTICAL SIGNALS FROM MULTIPLE SOURCES

    Methods and systems for real-time monitoring of optical signals from arrays of signal sources, and particularly optical signal sources that have spectrally different signal components. Systems include signal source arrays in optical communication with optical trains that direct excitation radiation to and emitted signals from such arrays and image the signals onto detector arrays, from which such signals may be subjected to additional processing.

  • METHOD FOR PRODUCING HUMAN RECOMBINANT INSULIN

    The invention relates to biotechnology and can be used for producing human recombinant insulin for preparing medicinal agents for the treatment of pancreatic diabetes. A variety of recombinant plasmid DNAs which contain an artificial gene and encode the human insulin precursor is proposed. The biosynthesis of a hybrid polypeptide is induced using isopropyl-thiogalactopyranoside so that the post-induction level of the hybrid polypeptide is equal to or greater than 25% of the total cellular protein. According to the claimed procedure, human insulin is produced by cultivating a producer strain containing one of the recombinant plasmids, isolating inclusion bodies, solubilizing and renaturing the fusion protein, and enzymatically degrading and chromatographically purifying said protein. The invention simplifies the process for producing human recombinant insulin and increases the yield thereof.

  • EXPRESSION CONSTRUCTS COMPRISING FUNGAL PROMOTERS

    The present invention provides promoters derived from a filamentous fungus. These promoters have application in the fields of molecular biology, microbiology,fungal genetics and production of biofuels and other products.

  • GASSING SYSTEM

    A gas-introduction system useful, for example, in biotechnology for supplying cells or microorganisms with oxygen. The gas-introduction system has a bubble column and a distributor. In the vessel there is situated a liquid medium which is to be supplied with gas. A vector is used as transport medium for the gas. The gas is introduced into the bubble column and here taken up by the vector. The vector is applied to the liquid surface via the distributor in droplet form, falls downward in the medium and releases to the medium some of the gas that has been taken up. At the bottom of the vessel is situated a collecting device in which the vector droplets coalesce and pass back into the bubble column. Disclosed are a bioreactor comprising the gas-introduction system and a method for introducing gas into a liquid medium, preferably an aqueous suspension containing cells or microorganisms.

  • Single Use Bead Mill

    The present invention relates to a device that incorporates a single use bead mill that is at least partially sterilized prior to use in the pharmaceutical, biopharmaceutical, biotechnology or related industries and is used for the disruption of cells or for homogenization within one or more fluid streams and is connected to a bioreactor, fermentor, container or process by way of single use tubing, connectors and/or various fluid flow components.

  • Single Use Centrifuge

    The present invention relates to a device that incorporates a single use centrifuge that is sterilized prior to use in the pharmaceutical, biopharmaceutical,biotechnology or related industries and is used for the removal of solids and/or other undesirable materials from one or more fluids and is connected to a bioreactor, fermentor, container or process by way of single use tubing, connectors and/or various fluid flow components.

  • DETECTION DEVICES AND METHODS

    The present invention relates to devices and methods for rapid and easy to use quantitative detection of one or more analytes in, for example, food, food ingredients, drinking water or pharmaceuticals. Analytes that can be detected by the devices and methods herein include, for example, adulterants, toxins, allergens, pathogens, pesticides, pharmaceuticals, pharmaceutical intermediates, biopolymers and biotechnology products.

  • DROUGHT TOLERANT PLANTS AND RELATED CONSTRUCTS AND METHODS INVOLVING GENES ENCODING MIR827

    Isolated polynucleotides and polypeptides and recombinant DNA constructs useful for conferring drought tolerance, compositions (such as plants or seeds) comprising these recombinant DNA constructs, and methods utilizing these recombinant DNA constructs. The recombinant DNA construct comprises a polynucleotide operably linked to a promoter that is functional in a plant, wherein said polynucleotide encodes a miR827 microRNA.

  • PLANTS WITH ALTERED ROOT ARCHITECTURE, RELATED CONSTRUCTS AND METHODS INVOLVING GENES ENCODING LEUCINE RICH REPEAT KINASE (LLRK) POLYPEPTIDES AND HOMOLOGS THEREOF

    Isolated polynucleotides and polypeptides and recombinant DNA constructs particularly useful for altering root structure of plants, compositions (such as plants or seeds) comprising these recombinant DNA constructs, and methods utilizing these recombinant DNA constructs. The recombinant DNA construct comprises a polynucleotide operably linked to a promoter functional in a plant, wherein said polynucleotide encodes a polypeptide useful for altering plant root architecture.

  • Anti-Gram Negative Bacteria Agent

    Provided are: a method for blocking the biosynthesis of an outer membrane protein (OMP) necessary for the survival of Gram-negative bacteria by inhibiting the formation of a YaeT complex in the outer membrane of the bacteria and an agent therefor for the purpose of basically solving a problem of the development of multidrug resistance in Gram-negative bacteria. Specifically disclosed is an anti-Gram-negative bacteria agent, wherein the agent exerts a bactericidal action, a growth-inhibiting action, and/or a drug efflux-inhibiting action on Gram-negative bacteria by inhibiting the formation of a YaeT complex. The agent is preferably a peptide molecule comprising an amino acid sequence consisting of at least LTLR or a peptide molecule comprising an amino acid sequence consisting of at least FIRL.

  • Physico-Chemical-Managed Killing of Penicillin-Resistant Static and Growing Gram-Positive and Gram-Negative Vegetative Bacteria

    Systems and methods for the use of compounds from the Hofmeister series coupled with specific pH and temperature to provide rapid physico-chemical-managed killing of penicillin-resistant static and growing Gram-positive and Gram-negative vegetative bacteria. The systems and methods represent the more general physico-chemical enhancement of susceptibility for a wide range of pathological macromolecular targets to clinical management by establishing the reactivity of those targets to topically applied drugs or anti-toxins.

  • Lactic Bacteria and Their Use in the Prevention of Diarrhea

    The present invention concerns a lactic composition useful for the prevention or treatment of diarrhea such as antibiotic associated diarrhea or "tourista." The composition according to the invention contains at least a bacterial strain selected from the group consisting of Lactobacillus acidophilus, Lactobacillus acidophilus I-1492, Lactobacillus casei and a mixture of thereof.

  • COMPOSITIONS AND METHODS FOR ELIMINATION OF GRAM NEGATIVE BACTERIA

    Oral drug delivery formulations which specifically administer antibacterial agents to the ileum, caecum, and/or the colon, without significant administration elsewhere in the gastrointestinal tract, are disclosed. The formulations include, as actives, a combination of a macrolide or aminoglysoside, or quinolone antibacterial and an anti-Gram-negative lipopeptide (polymyxin) antibacterial agent or other peptide antibacterials effective against Gram-negative bacteria. The formulations can be used to treat infections or unwanted colonization in the colon, and to provide effective decontamination of the colonic flora from unwanted or potentially pathogenic bacteria.

  • TRANSGENIC PLANTS WITH ENHANCED AGRONOMIC TRAITS

    This invention provides transgenic plant cells with recombinant DNA for expression of proteins that are useful for imparting enhanced agronomic trait(s) to transgenic crop plants. This invention also provides transgenic plants and progeny seed comprising the transgenic plant cells where the plants are selected for having an enhanced trait selected from the group of traits consisting of enhanced water use efficiency, enhanced cold tolerance, increased yield, enhanced nitrogen use efficiency, enhanced seed protein and enhanced seed oil. Also disclosed are methods for manufacturing transgenic seed and plants with enhanced traits.

  • RECOMBINANT VIRUS-LIKE PARTICLES ENCODED BY MULTI-GENE VECTOR

    The invention describes novel virus-like particles for use as vaccines, diagnostic tools and R&D tools based on recombinant DNA and cell cultivation techniques for production. The recombinant virus-like particles of the invention are assembled by polypeptide chains that incorporate several, in particular two or more, different epitopes which are selected either (a) from different viral strains of the same virus and/or (b) from different serotypes of the same virus and/or (c) from different viral strains specific for different hosts. These epitopes are then displayed on the particle surface.

  • Methods and DNA Constructs for Autoregulating Transgene Silencing

    This invention provides a method to autoregulate expression of a transgene susceptible to sRNA silencing by concomitantly transcribing RNA from DNA of a transgene and RNA from DNA from at least one sRNA silencing pathway gene. An aspect of the invention provides use of a recombinant DNA construct that includes DNA of a transgene and DNA of an sRNA silencing regulator. Also disclosed are transgenic cells and organisms having in their genome a recombinant DNA construct that includes DNA of a transgene and DNA of an sRNA silencing regulator.

  • BISPECIFIC ANTI-HER ANTIBODIES

    The invention provides anti-HER antibodies, including multispecific anti-HER antibodies, compositions comprising and methods of using these antibodies. Also provided herein are EGFR/HER3 multispecific antibodies that are less toxic than traditional EGFR antagonists.

  • GENE SEQUENCE VARIANCES IN GENES RELATED TO FOLATE METABOLISM HAVING UTILITY IN DETERMINING THE TREATMENT OF DISEASE

    The present disclosure describes the use of genetic variance information for folate transport or metabolism genes or pyrimidine transport or metabolism genes in the selection of effective methods of treatment of a disease or condition. The variance information is indicative of the expected response of a patient to a method of treatment. Methods of determining relevant variance information and additional methods of using such variance information are also described.

  • Genetic Variants Predictive of Cancer Risk in Humans

    The present invention discloses genetic variants that have been found to be predictive of risk of particular forms of cancer, in particular basal cell carcinoma and cutaneous melanoma. The invention provides methods of predicting risk of developing such cancers, and other methods pertaining to risk management of cancer utilizing such risk variants. The invention furthermore provides kits and computer systems for use in such methods.

  • URA5 Gene and Methods for Stable Genetic Integration in Yeast

    A novel gene encoding P. pastoris orotate-phosphoribosyl transferase (URA5) is disclosed. Methods for producing and selecting yeast strains capable of stable genetic integration of heterologous sequences into the host genome are also provided.

  • METHODS AND SYSTEMS FOR IN SILICO EXPERIMENTAL DESIGN AND FOR PROVIDING A BIOTECHNOLOGY PRODUCT TO A CUSTOMER

    Provided herein is a method and computer program product for designing and/or simulating a biotechnology experiment in silico; and for providing and generating revenue from a customized list of one or more biotechnology products and/or services related to the in silico designed or simulated biotechnology experiment or the product of that experiment. In illustrative examples, the products and or services are indirectly related to a biomolecule designed by the in silico designed biotechnology experiment. In addition, provided herein is a method and computer system for generating revenue, that includes providing a customer with a first computer program product for designing or performing a biotechnology experiment in silico; and providing the customer with access to a purchase function for purchasing a second computer program product for designing or performing a biotechnology experiment in silico. Typically, functionality of the first computer product is less then and/or different than the functionality of the second computer product.

  • UNSTRUCTURED RECOMBINANT POLYMERS AND USES THEREOF

    The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.

  • ORAL CARE COMPOSITIONS CONTAINING HUMAN RECOMBINANT INTERLEUKIN-1

    The present invention relates to oral care compositions comprising human recombinant interleukin-1 and methods thereof for keeping the oral cavity in a good condition, reducing oral malodor, and/or preventing or treating periodontal diseases. Preferably, the human recombinant interleukin-1 is human recombinant interleukin-1 alpha or beta.

  • SYNTHESIS OF LONG-CHAIN POLYUNSATURATED FATTY ACIDS BY RECOMBINANT CELLS

    The present invention relates to methods of synthesizing long-chain polyunsaturated fatty acids, especially eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic acid, in recombinant cells such as yeast or plant cells. Also provided are recombinant cells or plants which produce long-chain polyunsaturated fatty acids. Furthermore, the present invention relates to a group of new enzymes which possess desatorase or elongase activity that can be used in methods of synthesizing long-chain polyunsaturated fatty acids.

  • RECOMBINANT HUMAN ALPHA1- ANTITRYPSIN

    The present invention relates recombinant human .alpha.1-antitrypsin (rhAAT) comprising N-linked glycans, wherein at least 10% of said N-linked glycans are tetra-antennary glycans; and the degree of capping with sialic acid on said N-linked glycans (Z/A) is at least 50%. The invention further relates to rhAAT for use as a medicament, in particular for use in the prevention and/or treatment of a disease associated with AAT deficiency, and/or a disease involving neutrophil-mediated tissue damage.

  • MODIFICATION OF RECOMBINANT ADENOVIRUS WITH IMMUNOGENIC PLASMODIUM CIRCUMSPOROZOITE PROTEIN EPITOPES

    The present disclosure relates to adenovirus protein modifications to augment immune response to a transgene of a recombinant adenovirus and to circumvent pre-existing anti-adenovirus immunity. Some embodiments are directed to a recombinant adenovirus derived from a recombinant adenovirus plasmid vector, wherein the recombinant adenovirus plasmid vector comprises a nucleotide sequence encoding a Plasmodium circumsporozoite protein, or antigenic portion thereof, operably linked to a heterologous promoter and a modified capsid or core protein, wherein an immunogenic epitope of Plasmodium circumsporozoite is inserted into or replaces at least part of a capsid or core protein. Other embodiments are directed to a pharmaceutical composition or a malaria vaccine composition comprising a recombinant adenovirus according to the above embodiments. Further embodiments include a method of treating, preventing, or diagnosing malaria, comprising administering a therapeutic amount of the pharmaceutical composition or malaria vaccine composition in accordance with the above embodiment.

  • STABILIZATION OF LIQUID SOLUTIONS OF RECOMBINANT PROTEIN FOR FROZEN STORAGE

    The invention relates to a method for stabilizing a bulk solution of recombinant protein for frozen storage, which comprises providing a partially-purified solution of recombinant protein which has a monovalent salt concentration of at least 100 mM, and adding a carbohydrate to said solution in an amount sufficient that, upon freezing, the solution has a glass transition temperature of -56.degree. C. or higher.

  • Regulatory T Cells and Their Use in Immunotherapy and Suppression of Autoimmune Responses

    Based upon a strong correlation between regulator T cells (Treg cells) and suppressing or preventing a cytotoxic T cell response, provided are methods for the production of ex vivo activated and culture-expanded isolated CD4.sup.+CD25.sup.+ suppressor Treg cells for the prevention or suppression of immune reactions in a host, particularly in a human host, and including autoimmune responses. The resulting ex vivo culture-expanded Treg cells provide a sufficient amount of otherwise low numbers of such cells, having long term suppressor capability to permit therapeutic uses, including the preventing, suppressing, blocking or inhibiting the rejection of transplanted tissue in a human or other animal host, or protecting against graft vs host disease. Also provided are therapeutic and immunosuppressive methods utilizing the ex vivo culture-expanded Treg cells for human treatment, and high efficiency methods for research use

  • Regulatory T Cells and Their Use in Immunotherapy and Suppression of Autoimmune Responses

    Based upon a strong correlation between regulator T cells (Treg cells) and suppressing or preventing a cytotoxic T cell response, provided are methods for the production of ex vivo activated and culture-expanded isolated CD4.sup.+CD25.sup.+ suppressor Treg cells for the prevention or suppression of immune reactions in a host, particularly in a human host, and including autoimmune responses. The resulting ex vivo culture-expanded Treg cells provide a sufficient amount of otherwise low numbers of such cells, having long term suppressor capability to permit therapeutic uses, including the preventing, suppressing, blocking or inhibiting the rejection of transplanted tissue in a human or other animal host, or protecting against graft vs host disease. Also provided are therapeutic and immunosuppressive methods utilizing the ex vivo culture-expanded Treg cells for human treatment, and high efficiency methods for research use

  • APOE IMMUNOTHERAPY

    The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases.

  • GRANULYSIN IN IMMUNOTHERAPY

    Methods of stimulating or enhancing an immune response in a host are disclosed. The methods include contacting a monocyte with 15 kD granulysin thereby producing a monocyte-derived dendritic cell. In one example, the method further includes contacting the monocyte or monocyte-derived dendritic cell with a target antigen, such as a tumor antigen or an autoimmune antigen. In another embodiment, the method includes contacting the monocyte with an additional agent that enhances maturation of dendritic cells or induces immunological tolerance. The methods are of use in vivo, in vitro and ex vivo. In another aspect, the disclosure relates to compositions and methods for the treatment of tumors.

  • IMMUNOTHERAPY OF B-CELL MALIGNANCIES USING ANTI-CD22 ANTIBODIES

    B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 or CD19 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 and/or anti-CD19 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.

  • COMPOUNDS AND METHODS FOR IMMUNOTHERAPY AND DIAGNOSIS OF TUBERCULOSIS

    Compounds and methods for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more M. tuberculosis proteins and DNA molecules encoding such polypeptides. Such compounds may be formulated into vaccines and/or pharmaceutical compositions for immunization against M. tuberculosis infection, or may be used for the diagnosis of tuberculosis.

  • Recombinant Flavivirus Vaccines

    The invention provides recombinant flavivirus vaccines that can be used in the prevention and treatment of flavivirus infection. The vaccines of the invention contain recombinant flaviviruses including attenuating mutations.

  • DNA SEQUENCE AND PREPARATION OF GRASS POLLEN ALLERGEN PHL P4 BY RECOMBINANT METHODS

    The present invention relates to the provision of the genetic sequence of the major grass pollen allergen Phl p 4. The invention covers fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilised for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for the in vitro and in vivo diagnosis of pollen allergies.

  • RECOMBINANT ANTIBODIES AGAINST H1N1 INFLUENZA

    Antibodies that bind with high affinity to swine H1N1 virus are described. In vivo experiments showed that one such antibody is able to fully protect mice challenged with a lethal dose of swine H1N1 virus. The antibody is also able to cure mice in a therapeutic setting when treated as late as up to 60 hours (2.5 days) after infection with swine H1N1 virus. Also described are recombinant forms of this antibody.

  • RECOMBINANT ANTIBODIES AGAINST H1N1 INFLUENZA

    A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.

  • METHOD OF PRODUCING RECOMBINANT VITAMIN K DEPENDENT PROTEINS

    Methods for producing cell lines with high levels of biologically active recombinant vitamin K dependent proteins are described. The transfected cell lines do not include heterologous genes for processing enzymes and are not subject to selection pressure such as methotrexate resistance. Cell lines producing Factor VII/VIIa and Factor IX are described. These cell lines can be used for isolation of Factor VII/VIIa and/or Factor IX for treatment of Hemophilia.

  • DNA CONSTRUCT, AND PROCESS FOR PRODUCTION OF RECOMBINANT CHO CELL USING SAME

    Disclosed is a DNA construct that is useful for efficient production of recombinant CHO cells useful for the production of target proteins. The DNA construct is a construct comprising, from a 5' end toward a 3' end, a first homologous DNA fragment, a target protein gene, and a second homologous DNA fragment. The first and second homologous DNA fragments have homology allowing for homologous recombination with a part of a hypoxanthine-phosphoribosyltransferase enzyme (hprt) locus in a CHO cell genome and have a chain length of not less than 1 kbp.

  • PRODUCTION OF RECOMBINANT FACTOR IX IN A HUMAN HEPATOCYTE CELL LINE

    The invention relates to a recombinant human factor IX (FIX) characterized in that said factor is obtained by a preparation method comprising, or even consisting of, the steps which consist in causing the genetic material encoding the FIX to be expressed in vitro in a human hepatocyte cell line Huh7, recovering the cellular supernatant in which the FIX was secreted and, optionally, purifying the synthesized FIX.

  • MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION

    Disclosed herein are antisense compounds and methods for decreasing HBV mRNA, DNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate HBV-related diseases, disorders or conditions.

  • PLASMIDS AND METHODS FOR PEPTIDE DISPLAY AND AFFINITY-SELECTION ON VIRUS-LIKE PARTICLES OF RNA BACTERIOPHAGES

    The present invention relates to a system and method for controlling peptide display valency on virus-like particles (VLPs), especially including MS2 VLPs. In this method, large amounts of wild-type and low quantities of single-chain dimer coat proteins may be produced from a single RNA. Valency is controlled in immunogen (vaccine) production by providing a system that allows the production of large amounts of wild-type and low quantities of single-chain dimer coating proteins from a single RNA, allowing facile adjustment of display valency levels on VLPs, especially MS2 VLPS over a wide range, from few than one-on average--to as many as ninety per particle. This facilitates the production of immunogens and vaccines, including VLPs exhibiting low valency. Nucleic acid constructs useful in the expression of virus-like particles are disclosed, comprised of a coat polypeptide of MS2 modified by insertion of a heterologous peptide, wherein the heterologous peptide is displayed on the virus-like particle and encapsidates MS2 niRNA. Nucleic acid constructs are also disclosed which are useful in the expression of virus-like particles comprised of a coat polypeptide of PP7 modified by insertion of a heterologous peptide, wherein the heterologous peptide is displayed on the virus-like particle and encapsidates PP7 mRNA.

  • CONSENSUS SEQUENCE FOR INFLUENZA A VIRUS

    Pandemic A(H1N1) continues its global spread, and vaccine production is a serious problem. Protection by current vaccines is limited by the mutational differences that rapidly accumulate in the circulating strains, especially in the virus surface proteins. New vaccine strategies are focusing at conserved regions of the viral internal proteins to produce T cell epitope-based vaccines. T cell responses have been shown to reduce morbidity and promote recovery in mouse models of influenza challenge. We previously reported 54 highly conserved sequences of NP, M1 and the polymerases of all human H1N1, H3N2, H1N2, and H5N1, and avian subtypes over the past 30 years. Sixty-three T cell epitopes elicited responses in HLA transgenic mice (A2, A24, B7, DR2, DR3 and DR4). These epitopes were compared to the 2007-2009 human H1N1 sequences to identify conserved and variant residues. Seventeen T cell epitopes of PB1, PB2, and M1 were selected as vaccine targets by analysis of sequence conservation and variability, functional avidity, non-identity to human peptides, clustered localization, and promiscuity to multiple HLA alleles. The vaccines composed of these epitopes, being highly conserved and temporally stable, would be useful for any avian or human influenza A virus.

  • ANTIVIRAL PEPTIDES FROM AFRICAN SWINE FEVER VIRUS WHICH PREVENT THE BINDING OF THE VIRUS TO DLC8

    New antiviral peptides interfering the binding of the virus to DLC8. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8.

  • IMMORTALIZED AVIAN CELL LINES FOR VIRUS PRODUCTION

    The present invention relates to immortalized avian cell lines suitable for production of biologicals or viruses for vaccination. In particular, the cell lines are derived from primary cells which are transformed with at least two viral or cellular genes, one of which causes cell cycle progression whereas the other interferes with innate protective mechanisms of the cell induced by dysregulated replication. The invention moreover relates to the production of said immortalized cell lines and their use for producing biologicals or viruses for vaccination.

  • IMMORTALIZED AVIAN CELL LINES FOR VIRUS PRODUCTION

    The present invention relates to immortalized avian cell lines suitable for production of biologicals or viruses for vaccination. In particular, the cell lines are derived from primary cells which are transformed with at least two viral or cellular genes, one of which causes cell cycle progression whereas the other interferes with innate protective mechanisms of the cell induced by dysregulated replication. The invention moreover relates to the production of said immortalized cell lines and their use for producing biologicals or viruses for vaccination.

  • VACCINE AGAINST NEOPLASTIC OR CANCEROUS LESIONS CAUSED BY HUMAN PAPILLOMA VIRUS (HPV), PROCEDURES, USES AND METHODS

    Vaccine against neoplastic or cancerous lesions caused by human papillomavirus (HPV), which comprises E7 peptide spherical particles and, as an option, an adjuvant, where spherical particles may be oligomeric. The oligomeric spherical particles may have a diameter in the vicinity of 50 nm and a molecular weight in the vicinity of 700 kDa. The vaccine may be helpful to prevent or treat human papillomavirus (HPV)-related lesions or do both things at the same time.

  • VACCINE AGAINST NEOPLASTIC OR CANCEROUS LESIONS CAUSED BY HUMAN PAPILLOMA VIRUS (HPV), PROCEDURES, USES AND METHODS

    Vaccine against neoplastic or cancerous lesions caused by human papillomavirus (HPV), which comprises E7 peptide spherical particles and, as an option, an adjuvant, where spherical particles may be oligomeric. The oligomeric spherical particles may have a diameter in the vicinity of 50 nm and a molecular weight in the vicinity of 700 kDa. The vaccine may be helpful to prevent or treat human papillomavirus (HPV)-related lesions or do both things at the same time.

  • METHODS FOR DETECTING A MYCOBACTERIUM TUBERCULOSIS INFECTION

    Methods for detecting an infection with Mtb in a subject are disclosed. The methods include detecting the presence of CD8.sup.+ T cells that specifically recognize an Mtb polypeptide. The methods include in vitro assays for detecting the presence of CD8.sup.+ T cells in a biological sample, and in vivo assays that detect a delayed type hypersensitivity reaction. The methods also include detecting Mtb polypeptides and polynucleotides.

  • METHODS FOR DETECTING A MYCOBACTERIUM TUBERCULOSIS INFECTION

    Methods for detecting an infection with Mtb in a subject are disclosed. The methods include detecting the presence of CD8.sup.+ T cells that specifically recognize an Mtb polypeptide. The methods include in vitro assays for detecting the presence of CD8.sup.+ T cells in a biological sample, and in vivo assays that detect a delayed type hypersensitivity reaction. The methods also include detecting Mtb polypeptides and polynucleotides.

  • MYCOBACTERIUM TUBERCULOSIS FUSION PROTEIN AND USES THEREOF

    The present invention is related to a M. tuberculosis fusion protein, polynucleotide coding for said protein, and a vector and host cell that contain said polynucleotide. The present invention also involves the preparation of said fusion protein, and the use thereof in preventions and treatment of tuberculosis.

  • Use of Mycobacterium Bovis BCG killed by Extended Freeze Drying (EFD) For Preventing or Treating Atherosclerosis

    Use of Mycobacterium bovis BCG killed by Extended Freeze Drying (EFD) for preventing or treating atherosclerosis.

  • QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS

    Method of treating a bacterial infection other than a Mycobacterial infection, using a compound of formula (Ia) or (Ib) ##STR00001## a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, a tautomeric form thereof or a N-oxide form thereof, wherein the substituents R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, and R.sup.9 are as defined.

  • BACTERIOPHAGE AND ANTIBACTERIAL COMPOSITION COMPRISING THE SAME

    The present invention relates to a novel bacteriophage, more particularly, a bacteriophage that has a specific bactericidal activity against Salmonella typhimurium, Salmonella gallinarum, or Salmonella pullorum, a composition for the prevention or treatment of infectious diseases including salmonellosis and Salmonella food poisoning caused by Salmonella typhimurium, Fowl typhoid caused by Salmonella gallinarum, and Pullorum disease caused by Salmonella pullorum, which comprises the bacteriophage as an active ingredient, and an animal feed, drinking water, cleaner, and sanitizer which comprise the bacteriophage as an active ingredient. The present invention also provides important insights into prevention and control strategies against Salmonella infection and suggests that the use of bacteriophage can be a novel, safe, and effectively plausible alternative to antibiotics for the prevention of Salmonella infection in poultry.

  • ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS

    The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.

  • ANTIBACTERIAL 4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS HAVING MULTIPLE SUBSTITUENTS

    The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.

  • OXAZOLIDINONE DERIVATIVES CONTAINING NEW BICYCLIC GROUP, HAVING ANTIBACTERIAL ACTIVITY, AND METHOD FOR TREATING PATHOGENIC BACTERIAL INFECTIONS USING THE SAME

    The present invention relates to oxazolidinone derivatives containing new bicyclic group, having antibacterial activity, or a pharmaceutically acceptable salt thereof, a method for preparing the same, an antibacterial composition comprising the oxazolidinone derivative or a pharmaceutically acceptable salt thereof as an active ingredient, and a method for treating an infectious disease caused by pathogen using the same. The oxazolidinone derivative or a pharmaceutically acceptable salt thereof may exhibit excellent antibacterial activity against gram positive bacteria including various resistant strains.

  • Method for Cloning Cognate Antibodies

    The invention relates to a procedure for linking cognate pairs of V.sub.H and V.sub.L encoding sequences from a population of cells enriched in particular surface antigen markers. The linking procedure involves a multiplex molecular amplification procedure capable of linking nucleotide sequences of interest in connection with the amplification, in particular polymerase chain reaction (multiplex PCR). The method is particularly advantageous for the generation of cognate pair libraries as well as combinatorial libraries of variable region encoding sequences from immunoglobulins. The invention also relates to methods for generation of chimeric human/non-human antibodies and expression libraries generated by such methods.

  • Nucleotides and Nucleosides and Methods for their Use in DNA Sequencing

    The present invention relates generally to labeled and unlabled cleavable terminating groups and methods for DNA sequencing and other types of DNA analysis. More particularly, the invention relates in part to nucleotides and nucleosides with chemically cleavable, photocleavable, enzymatically cleavable, or non-photocleavable groups and methods for their use in DNA sequencing and its application in biomedical research.

  • MINICIRCLE DNA VECTOR PREPARATIONS AND METHODS OF MAKING AND USING THE SAME

    The present invention provides minicircle nucleic acid vector formulations for use in administering to a subject, wherein the minicircle nucleic acid vectors include a polynucleotide of interest, a product hybrid sequence of a unidirectional site-specific recombinase, and are devoid of plasmid backbone bacterial DNA sequences. Also provided are methods of producing the subject formulations as well as methods for administering the minicircle nucleic acid vector formulations to a subject. The subject methods and compositions find use in a variety of different applications, including both research and therapeutic applications.

  • SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION

    An agent for inhibiting translesion DNA replication comprises a non-natural adenine ribose analog represented by those as set forth in FIG. 1.

  • DNA DAMAGE REPAIR PROMOTER FOR ORAL APPLICATION, AND ELASTASE ACTIVITY INHIBITOR FOR ORAL APPLICATION

    To provide a DNA damage repair promoter for oral application and an elastase activity suppressor for oral application. The invention provides a DNA damage repair promoter and an elastase activity suppressor for oral application each containing, as an active ingredient, a bacterium belonging to the genus bifidobacterium.

  • RECOMBINANT VARICELLA-ZOSTER VIRUS

    A recombinant varicella-zoster virus; a process for producing the same; a pharmacological composition containing recombinant varicella-zoster virus; a vector containing a genomic gene of varicella-zoster virus and BAC vector sequence; cells containing the above vector; a fragment capable of homologous recombination with a genome of varicella-zoster virus; and a nucleic acid cassette containing the BAC vector sequence. For these, there is provided a process for producing recombinant varicella-zoster virus, comprising use of the BAC vector sequence.

  • RECOMBINANT NON-PATHOGENIC MAREK'S DISEASE VIRUS CONSTRUCTS ENCODING INFECTIOUS LARYNGOTRACHEITIS VIRUS AND NEWCASTLE DISEASE VIRUS ANTIGENS

    RECOMBINANT NON-PATHOGENIC MAREK'S DISEASE VIRUS CONSTRUCTS ENCODING INFECTIOUS LARYNGOTRACHEITIS VIRUS AND NEWCASTLE DISEASE VIRUS ANTIGENS

  • RECOMBINANT ADENO-ASSOCIATED VECTORS FOR TARGETED TREATMENT

    Novel adeno-associated virus (AAV) vectors in nucleotide and amino acid forms and uses thereof are provided. The isolates show specific tropism for certain target tissues, such as blood stem cells, liver, heart and joint tissue, and may be used to transduce stem cells for introduction of genes of interest into the target tissues. Certain of the vectors are able to cross tightly controlled biological junctions, such as the blood-brain barrier, which open up additional novel uses and target organs for the vectors, providing for additional methods of gene therapy and drug delivery.

  • PROCESS FOR PRODUCING RECOMBINANT HUMAN ENDOSTATIN ADENOVIRUS

    This invention discloses a production process for recombinant human endostatin adenovirus in order to optimize the procedure for small batch and mass industrialization. Exemplary process include steps of: (1) fermentation of eukaryotic cells (HEK293 cells) in the condition of 37.degree. C. and 5% CO.sub.2; (2) adenovirus infection; (3) collection of diseased cells; (4) freezing and thawing; (5) concentration by ultrafiltration; and (6) preparation and packaging of recombinant human endostatin adenovirus. The process is controllable and easy to operate. The concentration of adenovirus titers can reach 1.0.times.10.sup.12-3.0.times.10.sup.12 vp/ml.

  • RECOMBINANT HUMAN NAGLU PROTEIN AND USES THEREOF

    The present invention provides compositions comprising an isolated mixture of recombinant human NaGlu proteins in which a substantial amount of the NaGlu proteins in the mixture has increased levels of phosphorylated mannose that confer the proteins to be efficiently internalized into human cells. The present invention also provides methods of producing such mixture of NaGlu proteins, vectors used in transgenesis and expression, host cells harboring such vectors, and methods of isolating and purifying the mixture of NaGlu proteins. The invention further provides methods of treating NaGlu associated diseases.

  • ANTIMICROBIAL PRESERVATIVE COMPOSITIONS FOR PERSONAL CARE PRODUCTS

    A personal product antimicrobial preservative composition for preservation of topical personal care formulations is provided comprising [A] one or more undecylenic acid derivatives depicted by Formula (I), ##STR00001## [B] one or more octanoic acid derivatives depicted by Formula (II), ##STR00002## and [C] 2-phenoxy ethanol or 2-ethyl hexyl glyceryl ether or mixture of these two `liquid alcohol ethers`; wherein, each of the two components [A] and [B] is present in the range of 5 to 20% by weight and together [A] and [B] constitute 10 to 30% by weight and the `liquid alcohol ether`, component [C], is present 70 to 90% by weight of the total preservative composition. A method for preserving personal care product from microbial attack is provided containing an aqueous phase comprising three component composition from about 0.5 to 2.5% by weight of the total personal care formulation.

  • ANTIMICROBIAL ARTICLES

    The present disclosure describes a method for forming microporous and antimicrobial articles. The method comprises preparing an initial composition containing a semicrystalline polylactic acid material, a nonpolymeric aliphatic ester diluent, and a nucleating agent. The initial composition is heated to form a melt blended composition. Upon cooling, the melt blended composition phase separates into a composition having two continuous phases. A network of interconnected micropores may be formed by stretching the composition, by removing at least a portion of the nonpolymeric aliphatic ester diluent from the composition, or a combination thereof.

  • NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY

    The present invention generally concerns particular methods and compositions for antimicrobial therapy. In particular embodiments, the compositions target DXR. In specific embodiments, the compositions are electron-deficient heterocyclic rings.

  • Antimicrobial Composition and Uses Thereof

    A composition for prophylactic and/or therapeutic medicinal applications, or plant protection applications, in particular for the control of microorganisms, either planktonic or organized in biofilms. The composition includes at least one ion selected from hypohalite, at least one compound selected from lactoferrin, lactoferrin peptide, lysozyme, immunoglobulins or a combination thereof, optionally hypothiocyanite, and optionally at least one growth factor.

  • OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE

    Isolated antibodies and antigen binding fragments thereof directed against Ovr110 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an Ovr110-expressing cancer cells and alleviating or treating an Ovr110-expressing cancer in a mammal. The anti-Ovr110 antibodies modulate Ovr110 function or internalize upon binding to Ovr110 expressed by mammalian cells in vitro and in vivo. Compositions comprising an anti-Ovr110 antibody and a carrier as well as articles of manufacture or kits thereof are also provided. In addition, isolated nucleic acids encoding an anti-Ovr110 antibody, expression vectors containing the isolated nucleic acids, and host cells containing the vectors are provided.

  • TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES USING GENE THERAPY

    Provided herein are compositions and methods for treating and/or preventing neurodegenerative disease, such as Alzheimer's disease. In particular aspects, compositions administered herein encode a cellular immune response element. The compositions may be prepared and administered in such a manner that the cellular immune response element coding sequence is expressed in the subject to which the composition is administered. The compositions include expression systems, delivery systems, and certain cellular immune response element genes.

  • METHODS FOR DETECTING TH1 CELLS

    The inventors discovered that the adhesion molecule CAR, known to be localized in intracellular adhesion sites, functioned as an adhesion molecule for activated lymphocytes. Further, the inventors identified CARL, a novel CAR ligand expressed in lymphocytes, and clarified that the ligand was expressed selectively in Th1 cells. In addition, they found that anti-CAR antibodies could inhibit the adhesion of activated lymphocytes to CAR molecules. Thus, the present invention provides methods for detecting Th1 cells using CAR or anti-CARL antibodies, and methods of screening for inhibitors suppressing the adhesion of Th1 cells using the binding between CAR and CARL as an index. Furthermore, the present invention relates to methods of screening for inhibitors of the binding between CAR and CARL, antibodies that inhibit the binding between CAR and CARL, and therapeutic compositions comprising these antibodies. These are expected to be useful in diagnosing diseases, such as inflammation, in which infiltration of Th1 cells is involved, and in providing pharmaceutical agents for alleviating such diseases.

  • NUCLEIC ACID HAVING AN ANTI-METABOLIC SYNDROME EFFECT

    The problem of the present invention is to prove a medicament for decreasing body weigh, a medicament for decreasing visceral fat, a medicament for decreasing triglyceride in the liver, and a method for screening a medicament for ameliorating obesity and fatty liver. The problem is solved by a method comprising measuring an activity of a candidate material for inhibiting a sphingomyelin synthetase wherein if the candidate material has an activity for inhibiting a sphingomyelin synthetase, the candidate material is judged to have at least one function selected from the consisting of an anti-obesity drug, a drug for decreasing visceral fat, a drug for treating fatty liver and an agent for increasing adiponectin expression.

  • PACTAMYCIN ANALOGS AND METHODS OF USE

    Disclosed are pactamycin analogs, pharmaceutical compositions including the analogs, and methods of using the analogs, such as to inhibit tumor growth or a pathogenic infection such as a bacterial or parasitic infection. The pactamycin analogs have a general formula ##STR00001## where R.sup.1 is H, lower aliphatic, amide, acyl, or aminoacyl; R.sup.2 is --C(O)NR.sup.8R.sup.9 where R.sup.8 and R.sup.9 independently are hydrogen or lower aliphatic, or R.sup.1 and R.sup.2 together form a cyclic structure; R.sup.3 and R.sup.4 independently are hydrogen, hydroxyl, or lower aliphatic, or R.sup.2 and R.sup.3 together form a cyclic structure; R.sup.5 is hydrogen or acyl; R.sup.6 and R.sup.7 independently are hydrogen, hydroxyl, halogen, lower aliphatic, or amino.

  • METHODS TO IDENTIFY COMPOUNDS USEFUL FOR TUMOR SENSITIZATION TO DNA DAMAGE

    Cdc25A is herein identified as a substrate for .beta.-TrCP1- or .beta.-TrCP2-mediated ubiquitination and subsequent degradation via the ubiquitin-proteasome pathway. In particular, it has been found that interfering with .beta.-TrCP expression or function, or increasing .beta.-TrCP degradation, leads to accumulation of Cdc25A in a cell. Since degradation of Cdc25A is a key feature of the response to DNA damage, leading to a stall in the cell cycle during which the cell can repair the damage, Cdc25A accumulation can abolish this response, thereby sensitizing the cell to DNA damage. Described herein are assays for identifying .beta.-TrCP inhibitors, and method of using such inhibitors for modulating Cdc25A degradation, sensitization of tumor cells, and as adjuvants in cancer therapy based on DNA damaging agents.

  • HUMAN ANTIBODIES THAT BIND CD22 AND USES THEREOF

    The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.

  • TARGETED GENE DELIVERY FOR DENDRITIC CELL VACCINATION

    Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (DC). The virus envelope comprises a DC-SIGN specific targeting molecule. The methods and related compositions can be used to treat patients suffering from a wide range of conditions, including infection, such as HIV/AIDS, and various types of cancers.

  • NOVEL IMMUNOSTIMULATORY METHOD

    This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.

  • ANTAGONISTIC HUMAN LIGHT-SPECIFIC HUMAN MONOCLONAL ANTIBODIES

    Provided herein are antibodies that immunospecifically bind to an hLIGHT polypeptide; isolated nucleic acids encoding the antibodies; vectors and host cells comprising nucleic acids encoding the antibodies; methods of making the antibodies; and a method of treating a hLIGHT-mediated disease in a subject comprising administering to the subject the antibodies. In preferred embodiments, the anti-hLIGHT antibodies provided herein will ameliorate, neutralize or otherwise inhibit hLIGHT biological activity in vivo (e.g., the hLIGHT-mediated production or secretion of CCL20, IL-8 or RANTES from a cell expressing a hLIGHT receptor). Also provided herein is a method for the detection of hLIGHT in a sample as well as a method for ameliorating, neutralizing or otherwise inhibiting hLIGHT activity, e.g., in a human subject suffering from a disorder in which hLIGHT activity is detrimental.

  • NOVEL BACTERIOPHAGE AND ITS USE FOR PREVENTING PROLIFERATION OF PATHOGENIC BACTERIA

    The present invention relates to a novel phage, which is newly isolated and identified, a composition for inhibiting growth of bacteria or killing thereof comprising the same as an active ingredient, and the present invention can be diversely used as a composition for preventing or treating bacterial infectious diseases, a composition for treating ballast water, an antibiotic, an antiseptic, a feed additive and the like.

  • BACTERIOPHAGE LYSIN AND ANTIBIOTIC COMBINATIONS AGAINST GRAM POSITIVE BACTERIA

    The present invention provides compositions and methods for prevention, amelioration and treatment of gram positive bacteria, particularly Staphylococcal bacteria, with combinations of lysin, particularly Streptococcal lysin, particularly the lysin PlySs2, and one or more antibiotic, including daptomycin, vancomycin, oxacillin, linezolid, or related antibiotic(s).

  • USE OF PROBIOTIC BACTERIA TO PREVENT AND TREAT LISTERIAL INFECTIONS

    This invention relates to LAP-expressing probiotic bacteria and methods of use thereof to prevent and treat a pathogenic bacterial infection.

  • MONOCLONAL ANTIBODIES AGAINST PCBP-1 ANTIGENS, AND USES THEREFOR

    The present invention provides and includes monoclonal antibodies (MoAbs or mAbs) specific or preferentially selective for PCBP-1 antigens, hybridoma lines that secrete these PCBP-1 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect PCBP-1 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble form of PCBP-1. The present invention further includes chimeric and humanized antibodies, processes for producing monoclonal, chimeric, and humanized antibodies using recombinant DNA technology, and their therapeutic uses, particularly in the treatment of cancer. The present invention further includes methods and kits for the immunodetection and immunotherapy of cells for samples which express PCBP-1 antigens.

  • DROUGHT TOLERANT PLANTS AND RELATED CONSTRUCTS AND METHODS INVOLVING GENES ENCODING MATE-EFFLUX POLYPEPTIDES

    Isolated polynucleotides and polypeptides and recombinant DNA constructs useful for conferring drought tolerance, compositions (such as plants or seeds) comprising these recombinant DNA constructs, and methods utilizing these recombinant DNA constructs. The recombinant DNA construct comprises a polynucleotide operably linked to a promoter that is functional in a plant, wherein said polynucleotide encodes a MATE-efflux polypeptide.

  • VECTORS AND YEAST STRAINS FOR PROTEIN PRODUCTION: CA2+ ATPASE OVEREXPRESSION

    Lower eukaryote host cells in which an endogenous or heterologous Ca.sup.2+ ATPase is overexpressed are described. Also described are lower eukaryote host cells in which a calreticulin and/or ERp57 protein are overexpressed. These host cells are useful for producing recombinant glycoproteins that have reduced O-glycosylation.

  • PROCESS FOR THE PRODUCTION OF YEAST EXTRACTS HAVING LOW TURBIDITY

    The present invention describes a process to produce a yeast extract comprising a) subjecting yeast to autolysis; and b) subjecting the autolysate to solid/liquid separation and recovering the soluble fraction, whereby the solid/liquid separation in step b) is done at a pH of less than 5.1. The process of the invention is simple, has a high yield, and results in a yeast extract having low turbidity.

  • HIGH LEVEL PRODUCTION OF RECOMBINANT PROTEINS

    The present technology relates to the fields of biochemistry, molecular biology and medicine. In particular, the present technology relates to methods and compositions for increased expression of recombinant proteins.

  • LIPOTHEICHOIC ACID FROM LACTIC ACID BACTERIA AND ITS USE TO MODULATE IMMUNE RESPONSES MEDIATED BY GRAM-NEGATIVE BACTERIA,POTENTIAL PATHOGENIC GRAM-POSITIVE BACTERIA

    The invention relates to a composition for modulating the immune responses induced by Gram negative bacteria, potential pathogenic Gram positive bacteria and/or their derivatives, comprising lipoteichoic acid from lactic acid bacteria as an active ingredient. It also relates to the use of a lipoteichoic acid from lactic acid bacteria as an active ingredient and/or lactic acid bacteria producing it and/or its supernatant of culture, in the manufacture of a medicament, an oral or topical product for cosmetic, dermatological or opthalmological applications, a food or petfood composition for modulating bacterial colonisaion, immune responses and decreasing the inflammatory processes, associated with bacterially mediated disease and infection in the gastrointestinal tract, bone, skin, eye, ear, lung and rectal cavity. The invention also relates to lipoteichoic acid selected thereof.

  • Methods, compositions and kits for treating or preventing a disease associated with Gram-negative bacteria

    Compositions, methods and kits are provided for identifying at least one virulence factor of a Gram-negative bacterial strain, and for preparing attenuated bacterial strain vaccines or a modulator that selectively binds to or inhibits expression of the virulence factor. The Gram-negative bacterial strain is a short facultatively aerobic or micro-aerobic rod or an enteric strain including at least one pathogen selected from the group of: Salmonella, Escherichia, Yersinia, Klebsiella, Shigella, Enterobacter, Serratia, Pseudomonas, and Citrobacter. Novel genes encoding virulence factors are identified, so that non-virulent mutant strains are available for vaccine development.

  • Cna-B DOMAIN ANTIGENS IN VACCINES AGAINST GRAM POSITIVE BACTERIA

    The invention provides protective antigens which are useful in vaccine compositions to induce protection against gram positive bacteria, particularly against S. agalactiae, S. pyogenes, S. pneumoniae, S. aureus, S. suis, and S. equi.

  • STEROID ALKALOIDS AND USES THEREOF AS ANTIMICROBIAL AGENTS AGAINST ELECTRON TRANSPORT-DEFICIENT MICROBES AND AS POTENTIATORS FOR ANTIMICROBIAL AGENTS AGAINST PATHOGENIC BACTERIA

    The present invention includes novel compounds based on the tomatidine skeleton as well as composition comprising these compounds alone and in combination with known compounds, which exhibit antimicrobial activity against extracellular or intracellular electron transport-deficient microbes and/or increase the antimicrobial activity of aminoglycoside antibiotics against their targets, and which are useful as antibacterial agents for treatment or prophylaxis of monomicrobiotic or polymicrobic bacterial infections or for the reduction of antibiotic resistance development in animals or in humans, or for use as antiseptics or agents for sterilization or disinfection.

  • EXOPOLYSACCHARIDE OF SHIGELLA SONNEI BACTERIA, METHOD FOR PRODUCING SAME, VACCINE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

    For the first time, an O-specific polysaccharide antigen that is a Shigella Sonnei, phase I, exopolysaccharide has been produced and characterized, said exopolysaccharide being an authentic natural compound in the form of a bacterial capsular polysaccharide. The exopolysaccharide contains a non-toxic lipid component, namely non-hydroxylated fatty acids, and exhibits low pyrogenicity and high immunogenicity. Effective, highly specific and safe vaccines for the prophylaxis and/or treatment of Shigella sonnei shigellosis are developed on the basis of the above-mentioned exopolysaccharide, as well as pharmaceutical compositions with a broad spectrum of action, in particular, in modulating immune response.

  • Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative

    The present invention relates to a suspension formulation containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-a- nilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulph- onate, to a capsule pharmaceutical dosage form containing said suspension formulation, to a process for preparing said suspension formulation, to a process for preparing said capsule comprising said suspension formulation and to the packaging material for the finished capsule.